JANSSEN Alzheimer Immunotherapy is the sponsor of this clinical trial.
This is a multicenter, double-blind, placebo controlled, randomized, outpatient multiple dose study in male and female patients ages 50 to less than 89 years with mild to moderate AD.
Approximately 230 study sites in the US and Canada and up to 35 sites outside of North America will be involved. Patients will be randomized to receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.
- Diagnosis of probable AD
- Age from 50 to less than 89
- Mini-Mental Status Exam score of 16-26 inclusive
- Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD
- Stable doses of medications (cholinesterase inhibitors and memantine allowed)
- Caregiver able to attend all clinic visits with patient
- Significant neurological disease other than AD
- Major psychiatric disorder
- Significant systemic illness
- History of stroke or seizure, autoimmune disease, myocardial infarction within the last 2 years
- Smoking greater than 20 cigarettes per day
- Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications
- Prior treatment experimental immunotherapeutics or vaccines for AD
- Women of childbearing potential
- Presence of pacemakers, CSF shunts, or foreign metal objects in the eyes, skin or body
There are 239 clinical trial sites now open.
ClinicalTrials.gov Identifier: NCT00574132
- 60 Good Reasons to Subscribe to the Alzheimer's Reading Room
- Alzheimer's CareGiving -- Insight and Advice
- Test Your Memory for Alzheimer's (5 Best Self Assessment Tests)
- Communicating in Alzheimer's World
- Worried About Alzheimer's Disease -- You Should Be
- What is Alzheimer's? What are the Eight Types of Dementia?
- Does the Combination of Aricept and Namenda Help Slow the Rate of Decline in Alzheimer's Patients
- Alzheimer's Disease Statistics
- Is it Really Alzheimer's or Something Else?
- Ten Symptoms of Early Stage Alzheimer's
- Ten Tips for Communicating with an Alzheimer’s Patient
The Alzheimer's Action Plan
300 Tips for Making Life Easier
Bob DeMarco is the editor of the Alzheimer's Reading Room and an Alzheimer's caregiver. Bob has written more than 1,610 articles with more than 8,000 links on the Internet. Bob resides in Delray Beach, FL.
Original content Bob DeMarco, the Alzheimer's Reading Room